Nothing Special   »   [go: up one dir, main page]

Schoofs et al., 2019 - Google Patents

Broad and potent neutralizing antibodies recognize the silent face of the HIV envelope

Schoofs et al., 2019

View HTML @Full View
Document ID
5265016698921127954
Author
Schoofs T
Barnes C
Suh-Toma N
Golijanin J
Schommers P
Gruell H
West A
Bach F
Lee Y
Nogueira L
Georgiev I
Bailer R
Czartoski J
Mascola J
Seaman M
McElrath M
Doria-Rose N
Klein F
Nussenzweig M
Bjorkman P
Publication year
Publication venue
Immunity

External Links

Snippet

Broadly neutralizing antibodies (bNAbs) against HIV-1 envelope (Env) inform vaccine design and are potential therapeutic agents. We identified SF12 and related bNAbs with up to 62% neutralization breadth from an HIV-infected donor. SF12 recognized a glycan …
Continue reading at www.cell.com (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—AIDS or HTLV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency

Similar Documents

Publication Publication Date Title
Schoofs et al. Broad and potent neutralizing antibodies recognize the silent face of the HIV envelope
Rudicell et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo
Cale et al. Virus-like particles identify an HIV V1V2 apex-binding neutralizing antibody that lacks a protruding loop
Zhou et al. Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors
Zhou et al. A neutralizing antibody recognizing primarily N-linked glycan targets the silent face of the HIV envelope
Kwong et al. HIV-1 vaccines based on antibody identification, B cell ontogeny, and epitope structure
Kulp et al. Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding
Schommers et al. Restriction of HIV-1 escape by a highly broad and potent neutralizing antibody
Dubrovskaya et al. Vaccination with glycan-modified HIV NFL envelope trimer-liposomes elicits broadly neutralizing antibodies to multiple sites of vulnerability
Jardine et al. Minimally mutated HIV-1 broadly neutralizing antibodies to guide reductionist vaccine design
Bonsignori et al. Antibody‐virus co‐evolution in HIV infection: paths for HIV vaccine development
MacLeod et al. Early antibody lineage diversification and independent limb maturation lead to broad HIV-1 neutralization targeting the Env high-mannose patch
Sajadi et al. Identification of near-pan-neutralizing antibodies against HIV-1 by deconvolution of plasma humoral responses
Doria-Rose et al. New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency
Chuang et al. Structural survey of broadly neutralizing antibodies targeting the HIV-1 Env trimer delineates epitope categories and characteristics of recognition
Falkowska et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers
Falkowska et al. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4
McCoy et al. Holes in the glycan shield of the native HIV envelope are a target of trimer-elicited neutralizing antibodies
Scharf et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike
Zhou et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies
Huang et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
Jardine et al. Rational HIV immunogen design to target specific germline B cell receptors
Blattner et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers
Mukhamedova et al. Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses
Voss et al. Elicitation of neutralizing antibodies targeting the V2 apex of the HIV envelope trimer in a wild-type animal model